Participant flow

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma · Source last updated 2026-08-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Cohort 1, Dose Level 1 - Lenalidomide 25mg by mouth (PO) was given on days 1 to 10, plus, etoposide phosphate, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R). During cycle 1, Etoposide 50mg/m\^2/day, Vincristine 0.4 mg/m\^2 /day, and Doxorubicin 10 mg /m\^2/day were given as continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide, Vincristine 0.4 mg/m\^2 /day, and Doxorubicin were given as continuous intravenous infusion days 1 to 4. During cycles 2-6, doses of etoposide and doxorubicin were adjusted based on hematologic parameters during the previous cycle. During cycle 1, Prednisone 60 mg/m\^2 /day PO days 6 to 10. During cycles 2-6, Prednisone 60 mg/m\^2 /day PO days 1-5. During cycle 1, Cyclophosphamide 750 mg/m\^2 was given on day 10. During cycles 2-6, Cyclophosphamide 750 mg/m\^2 was given on day 5. Rituximab was administered on day 4 prior to the start of EPOCH during cycle 1 and on day 1 during cycles 2 to 6.

   id

   FG000

   title

   Lenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Did not complete last cycle of EPOCH-R2 due to progressive disease.

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         6

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         6

      type

      Received specified dose

   3. achievements

      1. group Id

         FG000

         num Subjects

         6

      type

      Underwent screening/staging

   4. achievements

      1. group Id

         FG000

         num Subjects

         6

      type

      Evaluated for response

   5. achievements

      1. group Id

         FG000

         num Subjects

         6

      type

      Off treatment

   6. achievements

      1. group Id

         FG000

         num Subjects

         6

      type

      Off study

   7. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      Disease progression on study

   8. achievements

      1. group Id

         FG000

         num Subjects

         5

      type

      COMPLETED

   9. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Phase I - Safety & Tolerability

2. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Refused further treatment

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Physician Decision

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      Received specified dose

   3. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      Evaluated for response

   4. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      Off treatment

   5. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      Off study

   6. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      Disease progression on study

   7. achievements

      1. group Id

         FG000

         num Subjects

         7

      type

      COMPLETED

   8. achievements

      1. group Id

         FG000

         num Subjects

         4

      type

      NOT COMPLETED

   title

   Phase II - Recommended Phase 2 Dose

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice